Together, the present study has established the role of nanocurcumin as adjunctive treatment to cisplatin in the ovarian cancer model through inhibition of TGF-β/PI3K/Akt and IL-6/JAK/STAT3 pathways. This evidence concerns the gene IL6 and ovarian carcinoma.